Oral paracetamol (acetaminophen) for cancer pain.

scientific article published on 12 July 2017

Oral paracetamol (acetaminophen) for cancer pain. is …
instance of (P31):
meta-analysisQ815382
scholarly articleQ13442814

External links are
P356DOI10.1002/14651858.CD012637.PUB2
P932PMC publication ID6369932
P698PubMed publication ID28700092

P50authorRae Jean Proeschold-BellQ90073384
Mairead McIntyreQ114776623
Ewan D McNicolQ117285416
Sheena DerryQ28036347
Philip J WiffenQ28036553
Robert Andrew MooreQ56192531
P2093author name stringBee Wee
Daniel B Carr
P2860cites workParacetamol and pain: the kiloton problemQ92480173
Oral morphine for cancer painQ24185873
NSAIDS or paracetamol, alone or combined with opioids, for cancer painQ24186655
Oral tapentadol for cancer painQ24187018
Buprenorphine for treating cancer painQ24187076
Caffeine as an analgesic adjuvant for acute pain in adultsQ24187350
Oxycodone for cancer-related painQ24187917
Codeine, alone and with paracetamol (acetaminophen), for cancer painQ24193511
Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer painQ24194524
Transdermal fentanyl for cancer painQ24197559
Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adultsQ24197826
Single dose oral paracetamol (acetaminophen) for postoperative pain in adultsQ24240759
COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expressionQ24536398
Prevalence of undertreatment in cancer pain. A review of published literatureQ24646347
Paracetamol for low back painQ26278817
Effectiveness of the World Health Organization cancer pain relief guidelines: an integrative reviewQ26741525
Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcomeQ26826917
Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trialsQ26998961
Influence of trial sample size on treatment effect estimates: meta-epidemiological studyQ27687577
Acetaminophen (paracetamol) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen: a randomized, double-blind, placebo-controlled cross-over trialQ44346404
COX-3: just another COX or the solitary elusive target of paracetamol?Q44378635
Is there an additive analgesic effect of paracetamol at step 3? A double-blind randomized controlled studyQ44705754
Early switching from morphine to methadone is not improved by acetaminophen in the analgesia of oncologic patients: a prospective, randomized, double-blind, placebo-controlled studyQ45068178
Association between analytic strategy and estimates of treatment outcomes in meta-analysesQ45303903
Pack size and paracetamol overdose: 16 years laterQ47437968
The relationship between cancer pain and quality of life in patients newly admitted to Wuhan Hospice Center of ChinaQ48286584
Single-patient multiple crossover studies to determine the effectiveness of paracetamol in relieving pain suffered by patients with advanced cancer taking regular opioids: A pilot studyQ50228176
Paracetamol, aspirin, and indomethacin induce endocrine disturbances in the human fetal testis capable of interfering with testicular descentQ50773873
Management of cancer painQ77769507
Intravenous paracetamol for pain relief in a patient with neuropathic painQ80626868
Dose-response in direct comparisons of different doses of aspirin, ibuprofen and paracetamol (acetaminophen) in analgesic studiesQ28199782
Impact of restricting paracetamol pack sizes on paracetamol poisoning in the United Kingdom: a review of the literatureQ28211791
The knowledge system underpinning healthcare is not fit for purpose and must changeQ28262850
Mechanism of action of paracetamolQ28303483
Effects of legislation restricting pack sizes of paracetamol and salicylate on self poisoning in the United Kingdom: before and after studyQ28365305
Use of paracetamol for suicide and non-fatal poisoning in the UK and France: are restrictions on availability justified?Q28379000
Liver transplant associated with paracetamol overdose: results from the seven-country SALT studyQ28607494
Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological studyQ28750315
Meta-assessment of bias in scienceQ29032830
Size is everything--large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effectsQ29619558
Meta-analyses involving cross-over trials: methodological issuesQ29620304
An evaluation of homogeneity tests in meta-analyses in pain using simulations of individual patient dataQ30592707
Mechanism of action of acetaminophen: is there a cyclooxygenase 3?Q31670168
Apparently conclusive meta-analyses may be inconclusive--Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analysesQ33372680
Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practiceQ33566361
The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis--a simulation studyQ34058272
Inhibition of Prostaglandin Synthetase in Brain explains the Anti-pyretic Activity of Paracetamol (4-Acetamidophenol)Q34212782
Therapeutic misadventure with paracetamol: fact or fiction?Q34229675
Treatment of pain or fever with paracetamol (acetaminophen) in the alcoholic patient: a systematic review.Q34229683
PlaceboQ34400388
Acetaminophen use during pregnancy, behavioral problems, and hyperkinetic disordersQ34406553
Random error in cardiovascular meta-analyses: how common are false positive and false negative results?Q34503295
Effect of the UK's revised paracetamol poisoning management guidelines on admissions, adverse reactions and costs of treatment.Q34571089
Journey of a late blooming biochemical neuroscientistQ34648031
The local antinociceptive effects of paracetamol in neuropathic pain are mediated by cannabinoid receptorsQ34655700
Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man.Q34691517
Clinical and economic characteristics of emergency department visits due to acetaminophen toxicity in the USA.Q36053701
Controlled clinical trials in cancer pain. How controlled should they be? A qualitative systematic review.Q36480717
The WHO analgesic ladder for cancer pain control, twenty years of use. How much pain relief does one get from using it?Q36500227
Long term effect of reduced pack sizes of paracetamol on poisoning deaths and liver transplant activity in England and Wales: interrupted time series analysesQ36594917
Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen): the multinational case-population SALT studyQ36597715
Paracetamol: not as safe as we thought? A systematic literature review of observational studiesQ36681854
The impact of study size on meta-analyses: examination of underpowered studies in Cochrane reviewsQ36721160
Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendationsQ37022616
Drug-induced liver injury in 2007.Q37137349
Clinical effectiveness: an approach to clinical trial design more relevant to clinical practice, acknowledging the importance of individual differences.Q37595967
Paracetamol metabolism and related genetic differencesQ37812385
GRADE guidelines: 7. Rating the quality of evidence--inconsistencyQ37908778
The role of paracetamol and nonsteroidal anti-inflammatory drugs in addition to WHO Step III opioids in the control of pain in advanced cancer. A systematic review of the literatureQ37962671
GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomesQ38006189
GRADE guidelines: 12. Preparing summary of findings tables-binary outcomesQ38011509
The long and winding road of non steroidal antinflammatory drugs and paracetamol in cancer pain management: a critical reviewQ38080300
The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic painQ38086926
What works for whom? Determining the efficacy and harm of treatments for painQ38102347
Pharmacological management of cancer pain in childrenQ38188163
Acetaminophen/paracetamol: A history of errors, failures and false decisionsQ38272082
Overview review: Comparative efficacy of oral ibuprofen and paracetamol (acetaminophen) across acute and chronic pain conditions.Q38296373
Cancer-Related Pain and Pain Management: Sources, Prevalence, and the Experiences of Children and Parents.Q38367317
Small studies are more heterogeneous than large ones: a meta-meta-analysisQ38470318
Non-steroidal anti-inflammatory drugs (NSAIDs) for cancer-related pain in children and adolescents.Q38664977
Pharmacological Management of Cancer-Related PainQ38672359
Oral nonsteroidal anti-inflammatory drugs (NSAIDs) for cancer pain in adults.Q38682609
Tramadol with or without paracetamol (acetaminophen) for cancer pain.Q38782574
Update on Prevalence of Pain in Patients With Cancer: Systematic Review and Meta-AnalysisQ38816973
Simple randomization did not protect against bias in smaller trials.Q38930666
Hydromorphone for cancer pain.Q38977999
Efficacy of paracetamol for acute low-back pain: a double-blind, randomised controlled trial.Q39203285
Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudesQ39307077
Analgesic effect of paracetamol on cancer related pain in concurrent strong opioid therapy. A prospective clinical studyQ39328475
Non-steroidal anti-inflammatory drugs as the first step in cancer pain therapy: double-blind, within-patient study comparing nine drugsQ39520581
The Association Between Pain and Quality of Life for Patients With Cancer in an Outpatient Clinic, an Inpatient Oncology Ward, and Inpatient Palliative Care UnitsQ39999599
Pain, Sleep Disturbance, and Quality of Life Among Palestinian Patients Diagnosed with CancerQ40329290
The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluationQ40382723
Antinociceptive effects of NCX-701 (nitro-paracetamol) in neuropathic rats: enhancement of antinociception by co-administration with gabapentinQ42577505
Lack of benefit from paracetamol (acetaminophen) for palliative cancer patients requiring high-dose strong opioids: a randomized, double-blind, placebo-controlled, crossover trialQ43190757
P921main subjectparacetamolQ57055
P304page(s)CD012637
P577publication date2017-07-12
P1433published inCochrane Database of Systematic ReviewsQ15750361
P1476titleOral paracetamol (acetaminophen) for cancer pain
P478volume7

Reverse relations

cites work (P2860)
Q98892340Indian Society for Study of Pain, Cancer Pain Special Interest Group Guidelines on Pharmacological Management of Cancer Pain (Part I)
Q39153206Opioids for cancer pain - an overview of Cochrane reviews.
Q38682609Oral nonsteroidal anti-inflammatory drugs (NSAIDs) for cancer pain in adults.
Q90402193Pharmacokinetics of ropivacaine in elderly patients receiving fascia iliaca compartment block
Q64356942Pregabalin for neuropathic pain in adults
Q92354755Real-life management of patients with breakthrough cancer pain caused by bone metastases in Spain
Q58103972Systematic review and meta-analysis on non-opioid analgesics in palliative medicine
Q60960809Treatment of Pain in Cancer: Towards Personalised Medicine
Q50048496Updates in palliative care - overview and recent advancements in the pharmacological management of cancer pain.

Search more.